Preclinical data suggest PARPis may enhance tumor immunogenicity through increased tumor infiltration by cytotoxic T cells18, activation of the STING pathway19, and accumulation of unrepaired DNA double-strand breaks which promote recruitment of antigen-presenting cells20. The gene discussed is STING1; the disease is neoplasm.